Related Experiment Video
Updated: Mar 11, 2026
09:02
Author Spotlight: Innovative Cancer Therapies with Iron Oxide Nanoparticles for Glioblastoma Treatment
Published on: September 27, 2024
3.2K
Targeted brain delivery nanoparticles for malignant gliomas.
Mauricio P Pinto1, Maximiliano Arce2,3, Basit Yameen4,5
1Laboratory of Immunology of Reproduction, Faculty of Chemistry & Biology, Universidad de Santiago de Chile, 9170022 Santiago, Chile.
Nanomedicine (London, England)
|November 24, 2016
Summary
Targeted nanoparticles offer new hope for treating malignant gliomas, overcoming the blood-brain barrier (BBB) challenges that limit conventional therapies for brain tumors.
Area of Science:
- Neuro-oncology
- Nanotechnology
- Pharmacology
Background:
- Malignant gliomas are aggressive brain tumors with high mortality rates.
- The blood-brain barrier (BBB) restricts drug delivery, hindering effective treatment.
- Nanoparticle (NP) technology shows promise for overcoming BBB limitations.
Purpose of the Study:
- To review therapeutic strategies for malignant gliomas using actively targeted nanoparticles (NPs).
- To analyze the challenges and mechanisms of crossing the BBB and blood-brain tumor barrier (BBTB).
- To critically assess clinical studies involving targeted NPs for glioma treatment.
Main Methods:
- Comprehensive literature review of targeted NP strategies for malignant gliomas.
- Analysis of BBB and BBTB transport mechanisms.
- Critical evaluation of clinical trial data for targeted NP therapies.
Main Results:
- Actively targeted NPs demonstrate potential for enhanced drug delivery across the BBB.
- Understanding NP-brain transport mechanisms is crucial for therapeutic efficacy.
- Clinical studies show promise but require further investigation.
Conclusions:
- Actively targeted NPs represent a promising therapeutic avenue for malignant gliomas.
- Further research is needed to optimize NP design and clinical application.
- Potential side effects and future directions for NP-based brain tumor therapy were discussed.
